- CDC News
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Clinical Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Anemia
- Neurology
- Pulmonology
Delayed Development of Keloid in Pierced Ear
Twelve years after having her ear pierced, a 58-year-old woman presented with a keloid on the right lobe's medial surface.
Twelve years after having her ear pierced, a 58-year-old woman presented with a keloid on the right lobe's medial surface. The lesion initially developed 2 years after the piercing, at which time it was excised and intralesional triamcinolone acetonide was administered intermittently. The keloid recurred 2 years later.
The patient sought treatment of the recurrent keloid 8 years later. The lesion was excised and a 2-year regimen of intralesional triamcinolone acetonide-given every 3 months-was begun.
FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial
January 9th 2025Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.
